Myelodysplastic Syndrome Clinical Trial
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
Summary
The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or Lymphoma. Your cancer has been difficult to treat (refractory) or has come back after treatment (relapse).
Primary Objective
To determine the safety and maximum tolerated dose of intravenous infusions of escalating doses of CD70-CAR T cells in patients (≤21 years) with recurrent/refractory CD70+ hematological malignancies after lymphodepleting chemotherapy.
Secondary Objectives
To evaluate the antileukemic activity of CD70-CAR T cells. We will determine the anti- leukemic activity of the CD70-CAR T cells in the bone marrow and in the treatment of extramedullary disease.
Full Description
The primary interventions are a lymphodepleting chemotherapy regimen (fludarabine and cyclophosphamide), followed by a single autologous infusion of CD70-CAR T cells.
Phase I study evaluating three (3) dose levels of CD70-CAR T cells.
Eligibility Criteria
Inclusion Criteria
Age ≤21 years old
Relapsed/refractory CD70+ hematological malignancy
Relapsed disease: Patients developing recurrent disease after a prior complete remission (CR)
Refractory disease: Patients with persistent disease despite 3 cycles of induction chemotherapy.
Relapsed/refractory CD70+ AML or MDS:
Relapsed disease that is CD70 positive
Refractory disease that is persistent despite 3 cycles of chemotherapy
Relapsed/refractory CD70+ B-cell ALL:
Relapsed disease that is CD70 positive and CD19 negative/dim or patients otherwise ineligible for CD19-directed therapies including:
Patients in 2nd or greater relapse
Patients with relapse after allogeneic HSCT
Relapsed/refractory CD70+ T-cell ALL:
Relapsed /refractory disease that is CD70 positive
Relapsed/refractory CD70+ lymphoma:
Relapsed disease that is CD70 positive and CD19 negative/dim or patients otherwise ineligible for CD19-directed therapies including:
Patients in 2nd or greater relapse
Patients with relapse after allogeneic HSCT
Estimated life expectancy of >12 weeks
Karnofsky or Lansky (age- dependent) performance score ≥50
Patients with a history of prior allogeneic HCT must be clinically recovered from prior HCT therapy, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to apheresis
Patient must have an identified HCT donor
For females of childbearing age:
i. Not lactating with intent to breastfeed
ii. Not pregnant with negative serum or urine pregnancy test within 7 days prior to enrollment
Exclusion Criteria
Known primary immunodeficiency
Known history of HIV positivity
Severe intercurrent bacterial, viral or fungal infection
History of hypersensitivity to cornstarch or hydroxyethyl starch
Patients with acute promyelocytic leukemia (APL)
Known contraindication to protocol defined lymphodepleting
chemotherapy regimen of Fludarabine/cyclophosphamide
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.